Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca cancer drug pipeline gets boost from European green light

Published 24/10/2014, 12:49
Updated 24/10/2014, 12:50
© Reuters A sign is seen at an AstraZeneca site in Macclesfield

© Reuters A sign is seen at an AstraZeneca site in Macclesfield

By Ben Hirschler

LONDON (Reuters) - AstraZeneca's (L:AZN) cancer drug pipeline received a boost on Friday, as European regulators recommended approval of an experimental medicine against ovarian cancer.

The green light from the European Medicines Agency (EMA) for olaparib, or Lynparza, is welcome news since the product hit a road bump in June when a U.S. panel voted against its accelerated approval.

AstraZeneca has flagged the medicine as a potential $2 billion-a-year seller.

Olaparib blocks an enzyme involved in cell repair and is designed for patients with certain hereditary gene mutations. It also has promise in treating other cancers, opening up a substantial market opportunity.

"We are committed to investigating the full potential of olaparib and have a number of studies underway in multiple tumour types including breast and gastric cancer," said Briggs Morrison, AstraZeneca's chief medical officer.

The treatment is expected to be the first drug in the so-called PARP inhibitor class to reach the market in Europe.

The EMA said its committee of experts on new drugs also recommended approval of Pfizer's (N:PFE) Duavive for oestrogen deficiency, Baxter International's (N:BAX) Rixubis for haemophilia and Clinuvel's (AX:CUV) Scenesse for phototoxicity.

Recommendations for marketing approval by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

An AstraZeneca spokeswoman said a final decision on olaparib's approval was now expected in January 2015. The British company also hopes to hear back from regulators on the approvability of the medicine in the United States by Jan. 3.

Cancer medicine is central to AstraZeneca's claims that it has a strong independent future, after fending off a $118 billion takeover bid from Pfizer (N:PFE) in May.

As part of its defence, the British drugmaker set out a bullish set of forecasts for its drug pipeline and predicted that group sales would climb 75 percent by 2023.

Most interest is focused on the company's rapidly developing line-up of experimental immunotherapy treatments, which boost the immune system's ability to fight cancer. Research presented at a cancer congress in Madrid last month suggests AstraZeneca is in a strong position in this field.

Shares in AstraZeneca pared losses by 1130 GMT to stand 0.6 percent down on the day, after falling as much as 2 percent earlier on news of an $11 billion share buyback plan by Pfizer.

© Reuters. A sign is seen at an AstraZeneca site in Macclesfield

Some investors saw the move as reducing the likelihood that Pfizer would renew its pursuit of AstraZeneca, although analysts cautioned against reading too much into the U.S. company's decision to continue its share repurchase plans.

(Editing by Tom Bergin and Clara Ferreira Marques)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.